Compare Abbott Laboratories (ABT) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs KKR & Co Inc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while KKR & Co Inc trades at $93.05 (market cap $85.42B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | KKR | |
|---|---|---|
Market Cap | $166.94B | $85.42B |
Sector | Health | Financials |
52-Week High | $136.62 | $152.16 |
52-Week Low | $82.57 | $83.88 |
Enterprise Value | $193.69B | $10.95B |
Dividend Yield | 2.63% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
KKR trades at $95.14, up 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows strong analyst sentiment with 24 buy ratings and a consensus price target of $127.43. Recent developments include a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, highlighting strategic growth initiatives. Financials reveal a P/E of 32.64 and net income margin of 14.51%, with Q1 2026 EPS beating expectations at $1.39 versus $1.26 estimated.
The outlook for KKR is positive, driven by expansion in renewable energy and private credit leadership, though risks include integration challenges from acquisitions and market volatility. Earnings growth and strategic deals present upside potential, with the current price offering a 34% discount to the analyst target. Investors should monitor Q2 2026 results due July 30, 2026, for further catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
